Meet Valinor Pharma. Meaningful therapies. Available to all.

Todd has built his career on business and organizational transformation across the pharmaceutical and medical device industries. He is known for his leadership and innovative, creative, and strategic approach to business, which have resulted in consistent revenue and value growth, evidenced by $1 billion+ capital raised, more than 25 product launches, and 100+ BD/M&A deals. In addition, he has founded more than 10 healthcare companies.

Prior to Valinor, Todd has held leadership positions at multiple pharmaceutical companies, including Tolmar Therapeutics, CEO of Iroko Pharmaceuticals, Zyla Life Sciences, and Assertio Therapeutics, as well as Chief Commercial Officer and Head of BD at Horizon Therapeutics.

Todd serves on several boards, including BVI Medical and Vault Pharma, and holds a B.A. in political science from Norwich University.

Ben is a highly accomplished and dynamic leader with 15 years of experience successfully launching companies, transforming performance, and accelerating growth within the healthcare and pharmaceutical industries.

Having held numerous President, CEO, and Chairman roles at companies like Iroko Pharmaceuticals and Apollo Care, Ben led many transformative company turnarounds in the pharmaceutical industry. Previously, Ben was General Manager of the Primary Care business and led Analytics at Horizon Therapeutics. His strategic vision and transformative leadership have resulted in commercial improvements of 5-15x. Ben has founded more than 10 healthcare companies, pioneered numerous first-to-market technologies/tools and innovative commercial models, vetted hundreds of BD deals, and led acquisitions of several pharma companies and products.

Ben serves on multiple boards across the pharmaceutical, technology, and nonprofit sectors. He holds an MBA, a Master of Engineering Management, and a B.S. in mechanical engineering, each from Northwestern University.

Clarke B. Futch is Chairman and Chief Executive Officer of HealthCare Royalty (HCRx). Mr. Futch is responsible for all of HCRx’s business activities, sets the strategic direction of the firm, and remains actively involved in new opportunities. He is considered an early pioneer in the royalty space, having been named in 2010 one of the future leaders in biotech finance by BioWorld, a leading industry publication. Since 2001, he has led/co-led 60+ royalty-related acquisitions with an aggregate value of nearly $4 billion. Mr. Futch brings over 30 years of experience in biopharmaceutical/healthcare investing and financing, having raised over $8 billion in equity and debt principal capital across 11 vehicles and executed more than 165 transactions, including royalty, equity, debt, and M&A financings. Before co-founding HCRx, Mr. Futch served as a partner at Paul Capital Partners where he co-managed the firm’s royalty activities as a member of the royalty management committee. Previously, he served as a founding member of the healthcare group at Thomas Weisel Partners (now Stifel) and as a vice president at Raymond James. Mr. Futch currently serves as Chairman of the Board of Managers of HCRx Holdings as well as Chairman of the Board of Directors of Valinor Pharma. Mr. Futch holds a B.A., magna cum laude, from Vanderbilt University and a J.D. from the University of Virginia School of Law.

Warren D. Cooper, MB, BS, BSc, MFPM, is the Chief Medical Officer and Head of the Portfolio Management Committee at HealthCare Royalty (HCRx). HCRx draws extensively on Dr. Cooper’s four decades of clinical, regulatory, and operational expertise as it evaluates new investment opportunities. Dr. Cooper previously served as an advisor to HCRx and has been well known to the firm, having worked on numerous projects for HCRx since the firm’s inception.

Dr. Cooper is a UK-trained physician with over 40 years of experience in the global pharmaceutical industry. With a background in cardiology and cardiac surgery, he spent 12 years with Merck in various positions, ultimately becoming the head of worldwide clinical research operations for Merck Research Laboratories across all therapeutic areas. Moving to AstraMerck (now AstraZeneca PLC), he led that company’s cardiovascular business division, with responsibility for all aspects of the business from in-licensing and development to commercialization (including sales and marketing). He was the founding CEO of Prism Pharmaceuticals, a specialty pharmaceutical company that he led from inception to its sale to Baxter International and a portfolio investment of Mr. Futch’s prior firm.

Dr. Cooper holds degrees in physiology, medicine, and surgery from The London Hospital (University of London) and is a Member of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom and of the International Society of Hypertension.

Raj is the Chief Executive Officer of I-MAB Biopharma Co., Ltd. and has over 30 years of experience leading and developing global business franchises and building companies. He has effectively led and grown organizations and supported multiple successful launches across therapeutic areas in the U.S. and globally.

Raj Kannan was previously the CEO of Aerie Pharmaceuticals. He led the successful merger of Aerie Pharmaceuticals to Alcon, Inc. where the all-cash transaction was consummated in mid-November 2022. He also served as an independent director of Amryt Pharmaceuticals until it was acquired by Chiesi in April of 2023.

Prior to joining Aerie, Mr. Kannan was Chief Executive Officer and President of Chiasma, Inc.. There, he led the organization through the approval and the launch of the first oral therapy in over a decade for patients with acromegaly and subsequently through the acquisition by Amryt Pharma Plc. Before that, Mr. Kannan was Chief Commercial Officer at Kiniksa Pharmaceuticals, and prior to Kiniksa, he served as the Global Head of the Neurology and Immunology business franchise at Merck KGaA, where he led and transformed the largest franchise into a growth franchise with $2 billion in annual revenues through significant strategic shifts in investment to support new product introductions and through recalibration of pipeline investments. Before that, Mr. Kannan spent 10 years at Boehringer Ingelheim International GmbH in the U.S., Canada, and in Germany, serving as Global Marketing Head of the Cardiovascular Franchise, where he was responsible for more than $3.5 billion in annual revenues.

Mr. Kannan is currently a member of the Board of Directors of Valinor Pharma.

Gil is the Chief Financial Officer at ACELYRIN, INC., where he leads the finance and accounting organization. He was previously Chief Financial Officer and Chief Operating Officer of Nektar Therapeutics where he led a team of more than 150 professionals in financial accounting and public reporting, business and strategic planning, corporate legal, intellectual property, government affairs, information technology and supply chain management. He previously served as Senior Vice President and General Counsel at Nektar, Vice President of Corporate Development at E2open, Inc. and Senior Director of Corporate Development at AltaVista Company. He began his career as corporate counsel at Wilson Sonsini Goodrich & Rosati.

Gil has a deep interest in the enterprise of discovering and developing innovative new medicines that can meaningfully improve healthcare for patients. He has been involved with life science growth companies in many different capacities over the last 25 years serving in senior leadership roles, as a board member and as an outside advisor. Over the course of his career, he has raised more than $1 billion in private and public market financing and generated more than $1 billion in realized value from strategic partnering transactions. In addition to being a member of the Board of Directors of Valinor Pharma, Gil also serves on the board and as audit committee chair of Rezolute, Inc., a clinical stage biopharmaceutical company dedicated to developing transformative therapies for patients suffering from debilitating metabolic diseases.

Gil holds a J.D. from the University of California Berkeley School of Law and a BA from the University of California Davis. He is also a CFA charter holder.

Anthony G. Rapsomanikis is a Managing Director at HealthCare Royalty (HCRx). Mr. Rapsomanikis opened HCRx’s San Francisco office in 2015 and is now focused primarily on HCRx’s activities in the mid-Atlantic region, including the greater NY metropolitan area, where he is responsible for transaction sourcing and structuring. Since joining HCRx in 2012, Mr. Rapsomanikis has worked on investments representing over $1.6 billion in transaction value. Prior to joining HCRx, Mr. Rapsomanikis worked as an analyst in the healthcare investment banking group at Stifel Nicolaus Weisel and its predecessor firm, Thomas Weisel Partners, where he was focused on mergers and acquisitions and debt and equity financings. Prior to Stifel, Mr. Rapsomanikis was an analyst at Silverwood Partners. Mr. Rapsomanikis currently serves as a member of the Board of Directors of Valinor Pharma. Mr. Rapsomanikis holds a B.B.A., cum laude, from the University of Massachusetts, Amherst.